KR101759874B1 - Skin external composition or Cosmetics composition for anti-wrinkle comprising compound of 11β-hydroxysteroid dehydrogenase type 1 inhibitor - Google Patents

Abstract

The present invention relates to a cosmetic composition for preventing skin aging or a composition for external application for skin comprising a compound inhibiting the activity of 11? -Hydroxysteroid dehydrogenase type 1, and more specifically, the present invention relates to a cosmetic composition for skin aging prevention comprising a compound inhibiting the activity of 11? -Hydroxysteroid dehydrogenase type 1, ) ≪ / RTI > derivatives of the formula < RTI ID = 0.0 >
[Chemical Formula 1]

Description

[0001] The present invention relates to a cosmetic composition or an external preparation for skin comprising a compound inhibiting the activity of 11? -Hydroxysteroid dehydrogenase type 1,

The present invention relates to a cosmetic composition comprising a compound inhibiting the activity of 11? -Hydroxysteroid dehydrogenase type 1, and more particularly, to a cosmetic composition containing a compound inhibiting the activity of 11? -Hydroxysteroid dehydrogenase type 1 as an active ingredient, Or an external preparation for skin.

The main areas of interest in functional cosmetic technology are products that delay skin aging and help to improve wrinkles, products that protect the skin from ultraviolet rays and the external environment, and products that help to whiten skin.

In order to develop a wrinkle-improving cosmetic for delaying aging of the skin, development of a functional raw material capable of exhibiting physiological efficacy in the skin should be preceded.

In general, wrinkles and skin elasticity, aging, and dry skin appear on aged skin, mostly due to changes in substrate proteins in the dermis. Since the dermis plays a role in supporting the strength and shape of the skin in the skin, when the morphological change occurs in this part when the aging proceeds, it plays a decisive role in the generation of wrinkles and skin wrinkles. Matrix metalloproteinases (MMPs) are typical enzymes that decompose these matrix proteins, and they are important factors in promoting skin aging by remarkably decomposing collagen and other matrix proteins in the skin. do.

Recently, the importance of urban aging prevention, in which skin aging is accelerated due to frequent exposure to mental internal stress or external harmful environment, is required. Studies have been carried out that physiological changes in the human body induced by external stress as well as natural aging caused by the passage of time, photoaging due to sunlight, may exacerbate skin aging.

According to Tiganescu, 11β-hydroxysteroid dehydrogease type 1 (hereinafter referred to as 11β-HSD1), a stress hormone regulatory enzyme, plays a significant role in skin aging. That is, the activity and expression of ll [beta] -HSDl increases with progress of skin aging (Tiganescu A et al, 2011; 131, 30-36), and the activity and expression of ll [beta] -HSDl is markedly increased, (Tiganescue et al, 2013; 123 (7): 3051-3060). In addition, when applying inhibitors of ll [beta] -HSDl, or making aged mice lacking the ll [beta] -HSDl gene, it was also found that the recovery of skin wounds was promoted and there was little change in dermal aging (Tiganescua et al, 2013 ; 123 (7): 3051-3060). Thus, it has been suggested that the control of 11 [beta] -HSD1 can inhibit or improve skin aging. 11β-HSD1 enzyme is an enzyme that converts inactive stress hormone into active stress hormone, and various mental stress as internal factors, and ultraviolet rays, pollutants and chemicals as external factors increase the activity and expression. In particular, the increase in the activity and expression of 11? -HSD1 due to ultraviolet rays is closely related to skin aging, and thus has been attracting attention as a new target for inhibiting skin aging.

On the other hand, various physiological effects such as treatment of skin wounds and treatment of metabolic diseases such as anti-diabetes have been reported to inhibit the expression and activity of 11? -HSD1. However, the results of research on the effect of inhibiting photoaging in skin are still insignificant.

The inventors of the present invention have made extensive efforts to overcome the problems of the prior art. As a result, the present inventors have found that the role of 11? -HSD1 activated by ultraviolet light is related to photoaging, Compounds that effectively inhibit activity were selected by in silico.

In this study, we investigated the interaction between proteins and materials, and expressed their chemical properties. Their functionalities are similar, but the new chemistry (protein-based active skeleton) Is one of the computational chemistry methods for the development of new materials having a structure. The Pharmacophore is the arrangement of the chemical conditions that are essential for the efficacy of the material using three-dimensional coordinates. In particular, the definition of active skeleton is very important for the binding of one protein to protein and its activity, which can be defined through known experimental data or sufficient structural analysis. The interaction between the protein and the material can be defined through the formation of hydrogen bonding (hydrophobic bonding) and hydrophobic (lipophilic) environments, and these become the chemical conditions for the active framework. Hydrogen bonding is expressed as a feature of the hydrogen bonding (HBA) and the hydrogen bonding accepting (HBD), and the hydrophobic environment is represented as a feature of (Lipo). It is defined in map form.

In the present invention, a compound having the structural formula (1) selected by in silico inhibits photoaging through increased expression of 11? -HSD1 and MMPs, thereby confirming the possibility of preventing or improving skin aging, thereby completing the present invention.

The primary object of the present invention is to provide a cosmetic composition or a composition for external application for skin comprising as an active ingredient a compound which inhibits the activity of 11? -Hydroxysteroid dehydrogenase type 1.

It is still another object of the present invention to provide a cosmetic composition for preventing skin aging or a composition for external application for skin comprising a compound inhibiting the activity of the 11? -Hydroxysteroid dehydrogenase type 1 and a physiologically acceptable cosmetic base.

According to one aspect of the present invention, there is provided a cosmetic composition for preventing skin aging comprising, as an active ingredient, a compound inhibiting the activity of 11? -Hydroxysteroid dehydrogenase type 1 .

In the present invention, a three-dimensional structure of 11β-hydroxysteroid dehydrogenase type 1 is used to detect 11β-hydroxysteroid dehydrogenase type 1 (11β-hydroxysteroid dehydrogenase type 1) dehydrogenase type 1) were selected.

In the present invention, the compound is preferably 1- [1- (1-adamantylacetyl) pyrrolidin-3-yl] -3,5-dimethyl-1H-pyrazole (1- (1-adamantylacetyl) pyrrolidin-3-yl] -3,5-dimethyl-1H-pyrazole).

[Chemical Formula 1]

In the experimental examples of the present invention, it was proved that the compound of the formula (1) effectively inhibits the expression of 11? -Hydroxysteroid dehydrogenase type 1 (11? -HSD1) and MMPs and restores collagen production, thereby preventing or improving skin aging.

In the example of the present invention, compounds capable of binding to the active site of ll [beta] -HSDl were selected in a hypothetical drug finding for ll [beta] -HSDl (Fig. 1) site, thereby inhibiting the activity of ll [beta] -HSDl, so that it can exhibit an effect equivalent to that of Compound 1 in the experimental examples.

In the present invention, the compound is contained in an amount of 0.01 to 10% by weight based on the total weight of the composition. If the amount is less than 0.01% by weight, the effect of inhibiting photoaging may be insignificant. On the contrary, if it exceeds 10% by weight, it may be undesirable from the viewpoint of economy.

In the present invention, the compound is characterized by exhibiting an inhibitory effect on the expression of 11? -Hydroxysteroid dehydrogenase type 1 (11? -HSD1).

According to the experimental example of the present invention, it was confirmed that the compound inhibits 11β-HSD1 overexpressed by ultraviolet light, and it was confirmed that the compound suppresses the production of cortisol, a stress hormone. As a result, the expression 2 of the present invention effectively inhibits the expression of 11? -HSD1, thereby reducing the body's stress hormone, thereby preventing or improving skin aging.

In the present invention, the compound is characterized by inhibiting the expression of Matrix metalloproteinases (MMPs) and restoring collagen production.

According to the experimental example of the present invention, the compound of the present invention can prevent or ameliorate skin aging by effectively inhibiting MMPs expression and restoring type I procollagen production.

In the present invention, the compound is characterized by having a skin damaging recovery effect.

According to the experimental example of the present invention, the compound can prevent or ameliorate skin aging by significantly restoring the reduction of the epidermal thickness by ultraviolet irradiation.

In the present invention, the skin aging prevention cosmetic composition is preferably characterized in that the skin aging is photoaging.

The term " photoaging " of the present invention is a phenomenon caused by external environmental factors. Ultraviolet rays are the most typical factor. Ultraviolet light leads to activation of proteolytic enzymes, chain breakage of substrate proteins and damage of biocomponents such as abnormal cross-linking, and the repetition of such mechanisms causes apparent skin aging. That is, unlike the endogenous aging caused by the genetic elements regardless of the external environment, the present invention provides a cosmetic composition for preventing or improving skin aging caused by photoaging caused by ultraviolet rays, .

In the present invention, the composition may be used as a skin lotion, a skin softener, a skin toner, an astringent, a lotion, a milk lotion, a moisturizing lotion, a nutrition lotion, a massage cream, a nutritional cream, a moisturizer cream, a hand cream, A cosmetic lotion, an essence, a pack, a soap, a cleansing foam, a cleansing lotion, a cleansing cream, a body lotion and a body cleanser.

According to another aspect of the present invention, there is provided a process for preparing 1- [1- (1-adamantylacetyl) pyrrolidin-3-yl] -3,5-dimethyl- The present invention provides a composition for preventing or improving skin aging which comprises as an active ingredient, [1- (1-adamantylacetyl) pyrrolidin-3-yl] -3,5-dimethyl-1H- pyrazole as an active ingredient.

[Chemical Formula 1]

A skin external preparation for preventing or improving skin aging comprising 1- [1- (1-adamantylacetyl) pyrrolidin-3-yl] -3,5-dimethyl- The composition is used for preventing or ameliorating skin aging comprising 1- [1- (1-adamantylacetyl) pyrrolidin-3-yl] -3,5-dimethyl- As described in the cosmetic composition for use in the present invention.

In the present invention, the composition for external application for skin may be prepared in any formulations conventionally produced in the art, and examples thereof include emulsion, cream, lotion, pack, foundation, lotion, essence and hair cosmetic . Specifically, the present invention relates to a skin lotion, a skin softener, a skin toner, an astringent, a lotion, a milk lotion, a moisturizing lotion, a nutrition lotion, a massage cream, a nutritive cream, a moisturizing cream, a hand cream, a foundation, Foams, cleansing lotions, cleansing creams, body lotions and body cleansers.

The composition of the present invention may contain other adjuvants in addition to the carrier, for example, preservatives, antioxidants, stabilizers, solubilizers, vitamins, pigments and perfumes.

In the present invention, each of the above compositions may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, external preparations such as syrups and aerosols, and sterilized injection solutions according to a conventional method. Creams, gels, patches, sprays, ointments, alerts, lotions, liniments, pastes or cataplasms.

Examples of carriers, excipients and diluents that can be contained in the composition include lactose, dextrose, sucrose, oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, Sucrose, lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

INDUSTRIAL APPLICABILITY As described above, the compound of formula (I) of the present invention inhibits the expression of 11? -HSD1 and MMPs, which are overexpressed by ultraviolet rays, as well as restores collagen production and skin damage, thereby preventing or improving skin aging.

Figure 1 is a three-dimensional structure of ll [beta] -HSDl.
Figure 2 shows two active framework maps that bind to ll [beta] -HSDl.
FIG. 3 shows the results of Experimental Example 1 in which the effect on human fibroblasts on cell proliferation in the treatment of the above formula (1) was measured.
Fig. 4 shows the results of Experimental Example 1 in which the effect on UVB-induced cell recovery in human fibroblasts treated with the above formula (1) was measured.
FIG. 5 shows the results of Experimental Example 2 in which the effect on human fibroblasts on the expression of 11? -HSD1 in the treatment of the above formula (1).
Fig. 6 shows the results of Experimental Example 2 in which the effect on the expression of cortisol in human fibroblasts treated with the above formula (1) was measured.
FIG. 7 shows the results of Experimental Example 3 in which the effect on the expression of MMP-1 messenger RNA in human fibroblasts by the above-mentioned Formula 1 was measured.
FIG. 8 shows the results of Experimental Example 3 in which the effect on the expression of MMP-1 protein in the human fibroblasts by the treatment of the above formula (1) was measured.
Fig. 9 shows the results of Experimental Example 3 in which the effect on the expression of type 1 procollagen in the human fibroblast was treated.
FIG. 10 shows the results of Experimental Example 4 in which the effect on the change of the skin layer thickness during the treatment of the above-described Formula 1 was measured on the three-dimensional skin model.
FIG. 11 shows the results of Experimental Example 4 in which the effect on the change of the skin layer thickness during the treatment of the above-described Formula 1 was measured on the three-dimensional skin model.

Hereinafter, the present invention will be described in more detail with reference to Examples. These embodiments are only for illustrating the present invention, and thus the scope of the present invention is not construed as being limited by these embodiments.

Example  1: Excavation of the general formula (1)

The hypothetical new drug search for 11β-HSD1 (FIG. 1) determined the active site in which the material binds in the three-dimensional structure of the known 11β-HSD1 and 5 Å around it to determine the active skeleton map for this region One map was defined to contain 5-6 elements, and finally two active skeleton maps were completed (Fig. 2). A compound library was searched using this active skeleton map, and a substance which is considered to be a candidate for 11β-HSD1 inhibitory activity was selected. The compound library has been able to search for multiple conformations of three-dimensional structures to include all chemically possible conformers. In the case of the compound library, a focused library containing about 300 compounds was constructed in consideration of the characteristics of the cosmetic material in order to meet the object of the present invention.

For the present invention, eleven compounds that are predicted to inhibit 11? -HSD1 activity ultimately were selected through the above-described virtual drug search process.

Experimental Example  1: 11 [beta] HSD1  Verify Active

The compounds of formulas (1) to (11) selected in Example 1 were purchased from Chembridge (USA) and dissolved in DMSO (dimethyl sulfoxide).

CHO cells overexpressing 11? -HSD1 were inoculated in 96-well culture dishes at a density of 2.5 × 10 ⁴ cells and cultured in a 5% CO ₂ incubator at 37 ° C. for 24 hours. 160 nM cortisone and the compound were treated for 3 hours, and HTRF (homogenous time-resolved fluorescence) assay was performed.

Table 1 below shows the measured inhibition rates of 11? -HSD1 activity of the compounds of the formulas (1) to (11). As a result, it was confirmed that the compound of formula (I) inhibits the activity of 11? -HSD1 much better than other compounds.

[Table 1]

Experimental Example  2: Confirmation of cell proliferation effect of Compound 1

Compound 1 (hereinafter referred to as Compound 1) selected in Example 1 was purchased from Chembridge (USA) and dissolved in DMSO (dimethyl sulfoxide) to be used as a sample.

Human fibroblasts were inoculated in a 96-well culture dish at a density of 4 × 10 ⁴ cells and cultured in a 5% CO ₂ incubator at 37 ° C. for 24 hours to confirm the cell proliferation effect of the compound 1 in human fibroblasts. After UVB irradiation at 15 mJ, compound 1 was added and cultured for 24 hours. Cells were collected and crystallized with a 0.5% solution of MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide DMSO and absorbance was measured.

As a result, as shown in FIG. 4, the cell proliferation efficiency was shown according to the concentration of the compound 1, and as shown in FIG. 5, it showed the effect of restoring cells damaged by UVB.

Experimental Example  3: Stress Inhibitory Effect of Compound 1

It was inoculated in human fibroblasts at a density of 11β-HSD1 in the messenger RNA expression of human fibroblasts to determine the inhibitory effect of 6 well cell 4 X 10 ⁵ on a Petri dish leading to UVB of the compound 1 37 ℃, 5% CO ₂ incubator for 24 hours. UVB was irradiated at 15 mJ, Compound 1 was added thereto, and cultured for 24 hours. Cells were recovered and RNA was isolated by adding 1 ml of trizol (RNA iso, DAKARA, Japan). RNA was quantitated at 260 nm using an ultraviolet detector and cDNA was synthesized (Reverse Transcriptase Mix, ELPIS biotech, Korea). RT-PCR was performed using a PCR machine (Step One Plus, Applied Biosystems, USA) and addition of SYBR Green supermix (Applied Biosystems, USA) with 11? -HSD1 primer and cDNA. The primers and reaction conditions were as shown in Table 2 below, and the expression level of the 11? -HSD1 gene was corrected for the? -Actin gene.

[Table 2]

In order to confirm the UVB-induced cortisol inhibitory effect of Compound 1, human fibroblasts were inoculated in a 6-well cell culture dish at a density of 4 × 10 ⁵ and cultured in a 5% CO ₂ incubator at 37 ° C. for 24 hours Respectively. UVB was irradiated at 15 mJ, and Compound 1 was added thereto, followed by further incubation for 24 hours, and the medium was recovered. The recovered medium was centrifuged at 12,000 rpm for 10 minutes to remove impurities and assayed using a cortisol ELISA kit (R & D system, USA).

As a result, as shown in FIGS. 6 and 7, the expression of 11? -HSD1 and cortisol was inhibited depending on the concentration of Compound 1.

Experimental Example  4: Effect of compound 1 on collagen degradation inhibition

In order to confirm the inhibitory effect of UVB-induced MMP-1 induced by Compound 1 on human fibroblasts, human fibroblasts were cultured in the same manner as described in Experimental Example 2, and UVB and Compound 1 were added After 24 hours of additional culture, the amount of messenger RNA expression of MMP-1 was confirmed. The primers and reaction conditions are shown in Table 3 below, and the expression level of the MMP-1 gene was corrected for the β-actin gene.

[Table 3]

In order to confirm the UVB-induced inhibition of MMP-1 protein expression of the compound 1 in human fibroblasts, human fibroblasts were inoculated in a 6-well cell culture dish at a density of 4 × 10 ⁵ , CO ₂ incubator for 24 hours. UVB was irradiated at 15 mJ, Compound 1 was added at a concentration (1, 10 / / ml), cultured for 72 hours, and cells were recovered. Cells were lysed with 100 μl of lysis buffer, and proteins were extracted and quantified at 595 nm using the Bradford assay. The proteins were electrophoresed using sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and protein bands were transferred to PVDF (Polyvinylidene fluoride, Bio-Rad, USA), and the amount of protein expressed by ECL (Enhanced chemiluminescence, ThermoScientific, USA) .

As a result, as shown in FIGS. 8 and 9, the inhibitory effect of MMP-1 on the compound 1 in a concentration-dependent manner was confirmed.

Also, in the type 1 procollagen produced were inoculated to human fibroblasts to determine a remedial effect at a density of 4 X 10 ⁵ on a 6 well cell culture plate 37 ℃, 5% CO ₂ incubator induced by UVB of the compound 1 24 Time. UVB was irradiated at 15 mJ, and Compound 1 was added thereto, followed by further incubation for 24 hours, and the medium was recovered. The recovered medium was centrifuged at 12,000 rpm for 10 minutes to remove impurities and assayed using a type 1 procollagen EIA (enzyme immunoassay) kit (DAKARA, Japan).

As a result, as shown in Fig. 10, the compound 1 recovered the type 1 procollagen in a concentration-dependent manner.

Experimental Example  5: Three-dimensional artificial skin damage of Compound 1 Recoverability  Confirm

 In order to evaluate the recovery effect of the compound 1 on the skin layer damage, the three-dimensional artificial skin tissue was used to evaluate the in vivo model.

After epidermal tissue (Skin Ethics, Nikoderm Research Inc., France) was stabilized in growth media for 24 hours, Compound 1 was added to the medium. UVB 40mJ was irradiated three times every 4 hours, and after culturing for 72 hours, epidermal tissue was collected and H & E staining was performed.

As a result, as shown in Figs. 10 and 12, the epidermal tissue irradiated with UVB was compared with the tissue not irradiated with UVB, and the decrease in epidermal thickness was noticed, and the compound 1 significantly restored the decrease in epidermal thickness .

Formulation Example  1: Manufacture of Toner

The toner preparation containing the compound 1 was prepared in a conventional manner according to the composition components and composition ratios shown in Table 4 below.

[Table 4]

Formulation Example  2: Preparation of lotion agent

Lotion agents containing Compound 1 were prepared according to the conventional methods according to the compositional components and composition ratios shown in Table 5 below.

[Table 5]

Formulation Example  3: Manufacture of cream agent

The creams containing the compound 1 were prepared in a conventional manner according to the compositional components and composition ratios shown in Table 6 below.

[Table 6]

Claims (8)

The present invention relates to a cosmetic composition for preventing skin aging comprising as an active ingredient a compound which inhibits the activity of 11? -Hydroxysteroid dehydrogenase type 1, wherein the compound is 1- [1- (1-adamantyl Acetyl) pyrrolidin-3-yl] -3,5-dimethyl-1H-pyrazole (1- Wherein the anti-aging cosmetic composition comprises:
[Chemical Formula 1]

delete 2. The cosmetic composition for preventing skin aging according to claim 1, wherein the compound is contained in an amount of 0.01 to 10% by weight based on the total weight of the composition.
The cosmetic composition for preventing skin aging according to claim 1, wherein the compound has 11? -HSD1 activity inhibiting activity and MMP-1 expression inhibiting activity.
The cosmetic composition for preventing skin aging according to claim 1, wherein the compound has an effect of restoring collagen production and restoring skin damage.
The cosmetic composition for preventing skin aging according to claim 1, wherein the skin aging is photoaging.
The composition according to claim 1, wherein the composition is at least one selected from the group consisting of a lotion (skin lotion), a skin softener, a skin toner, an astringent, a lotion, a milk lotion, a moisturizing lotion, a nutrition lotion, a massage cream, Wherein the composition is selected from the group consisting of nutritional essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion and body cleanser.
(1- [1- (1-adamantylacetyl) pyrrolidin-3-yl] -3,5-dimethyl-1H-pyrazole -yl] -3,5-dimethyl-1H-pyrazole) as an active ingredient for preventing or ameliorating skin aging.
[Chemical Formula 1]

Images